Evidence map›Paper›PMID 41063390›Full record

ArticleJNCI cancer spectrum2025

Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer.

William S Chen, Abuzar Moradi Tuchayi, Ali Sabbagh, Inkyu Kim, Evan Porter, Amir Ashraf-Ganjouei, Yun Rose Li, Alon Witztum, Abhejit Rajagopal, Steven N Seyedin and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JNCI cancer spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

William S ChenDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-3717-670X
Abuzar Moradi TuchayiDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States.
Ali SabbaghDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0001-6826-959X
Inkyu KimDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0009-0008-8670-6595
Evan PorterDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-6273-5788
Amir Ashraf-GanjoueiDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, United States.
Yun Rose LiDepartment of Radiation Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, United States.ORCID 0000-0002-8077-4975
Alon WitztumDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, United States.
Abhejit RajagopalDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States.
Steven N SeyedinDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-6841-968X
Roxanna JuarezDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0003-2684-5258
Peter R CarrollDepartment of Urology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-1086-4334
Felix Y FengDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0001-9756-4037
Eric J SmallDivision of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Thomas A HopeDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-2228-5823
Julian C HongDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0001-5172-6889

Funding

ASTRO-PCF Career Development Award to End Prostate Cancer
6 · The paper itself

Abstract

backgroundMetastasis-directed radiotherapy (MDT) is the mainstay in management of oligometastatic prostate cancer (PCa), and PSMA-PET is currently the most sensitive imaging modality for localizing PCa metastases. The efficacy of MDT guided by PSMA-PET imaging with and without androgen deprivation therapy (ADT) ± androgen-receptor pathway inhibitor (ARPI) has not yet been well characterized. We sought to evaluate the efficacy of PSMA PET-guided MDT.

methodsThis is a single-institutional retrospective study of patients diagnosed with metastatic PCa by PSMA-PET imaging who were treated with MDT. Survival analyses were performed using the Kaplan-Meier method with Cox proportional hazards testing for significance. Cumulative incidence analyses were performed with Gray's testing for significance.

resultsOne hundred and ninety-four metastatic lesions from 101 patients identified by PSMA PET were irradiated with MDT. Forty-seven of the 79 (59%) patients with hormone-sensitive PCa (HSPC) received ADT ± ARPI along with MDT. Four of 194 lesions (2.1%) demonstrated radiographic progression after MDT, with a median follow-up of 22.4 months. Two-year cumulative incidence of progression from HSPC to CRPC was 11% in patients who received ADT ± ARPI and 35% in those who did not (P = .027). Median biochemical progression free survival of patients with CRPC, HSPC treated without ADT or ARPI, and HSPC treated with ADT ± ARPI was 5.4, 7.6, and 43.9 months, respectively (P < .0001). No Grade 3-5 adverse effects were observed.

conclusionsMDT guided by PSMA-PET imaging is well-tolerated and delays biochemical progression in patients with CRPC and HSPC, with a greater effect observed in patients also receiving ADT ± ARPI.

Indexed as

Androgen AntagonistsProstatic NeoplasmsRadiotherapy, Image-GuidedAgedAged, 80 and overGlutamate Carboxypeptidase IIHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisPositron-Emission TomographyProportional Hazards ModelsProstate-Specific AntigenRetrospective StudiesAndrogen AntagonistsGlutamate Carboxypeptidase IIProstate-Specific Antigen

Identifiers

PMID41063390
PMCPMC12582589

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.